Fetroja Approved for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
Infectious Disease
One-Fifth of Those With SARS-CoV-2 Infection Asymptomatic
No significant differences seen in mean cycle threshold values for asymptomatic, symptomatic patients.
Point-of-Care COVID-19 Antibody Test Gets Emergency Use Authorization
The reissued EUA allows for fingerstick blood samples to be tested in point-of-care settings.
Phase 3 Trial of Janssen’s COVID-19 Vaccine to Evaluate Single Dose Regimen
JNJ-78436735 is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein.
Trials Testing Convalescent Plasma for COVID-19 Expanded
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.
PrEP Prescribing Low in the US, Even Among HIV Care Providers
About half of survey participants recruited from HIV CME courses reported ever prescribing PrEP
COVID-19 Death Toll Nears 200,000 in the United States
Conceivable that death toll could reach 300,000 if Americans start to relax social distancing measures
Tocilizumab Reduces Need for Mechanical Ventilation in COVID-19 Pneumonia Trial
Patients treated with tocilizumab were 44% less likely to progress to mechanical ventilation or death compared with placebo.
Warning Issued on Potentially Deadly Mosquito-Borne Virus in Michigan
Suspected case of EEE in a resident of Barry County was announced earlier this week by state officials
MPR Weekly Dose Podcast Episode 51
This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There’s the Janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; And a retrospective study compared cardiac events with azithromycin and amoxicillin use.
